Evogene Ltd. (NYSE: EVGN) reported Q3 EPS of ($0.17), $0.06 worse than the analyst estimate of ($0.11). Revenue for the quarter came in at $3.16 million versus the consensus estimate of $4.2 million.

For earnings history and earnings-related data on Evogene Ltd. (EVGN) click here.